REG - RUA Life Sciences - Director/PDMR Shareholding

Rua Life SciencesAnnouncement

Today 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250506:nRSF4837Ha&default-theme=true

RNS Number : 4837H  RUA Life Sciences PLC  06 May 2025

6 May 2025

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

 

Director/PDMR Shareholding

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device
businesses focused on the exploitation of the world's leading long-term
implantable biostable polymer (Elast-Eon™), announces that it has been
notified that Lachlan Smith, Chief Financial Officer of the Company, on 2 May
2025, purchased 20,228 ordinary shares in the Company at 11.86 pence per
ordinary share.

Following this purchase, Lachlan Smith is interested in 130,508 ordinary
shares in the Company, representing approximately 0.21 per cent. of the
Company's issued ordinary share capital.

 

The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Lachlan Smith
 2    Reason for the notification
 a)   Position/status                                              Chief Financial Officer
 b)   Initial notification /Amendment                              Initial
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         RUA Life Sciences plc
 b)   LEI                                                          213800BMVB22PVOJ9Z28
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
      Transaction
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each

      Identification code

                                                                   ISIN: GB0033360586
 b)   Nature of the transaction                                    Purchase of Ordinary Shares
 c)   Price(s) and volume(s)

Price(s)     Volume(s)
                                                                   11.86 pence  20,228

 
 d)   Aggregated information                                       N/A (Single transaction)

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      2 May 2025
 f)   Place of the transaction                                     London Stock Exchange, AIM

 

d)

 

Aggregated information

- Aggregated volume

- Price

N/A (Single transaction)

e)

Date of the transaction

2 May 2025

f)

Place of the transaction

London Stock Exchange, AIM

 

- Ends -

 

For further information contact:

 

 

 RUA Life Sciences

 Bill Brown, CEO                                                       Tel: +44 (0)1294 317073

 Lachlan Smith, CFO                                                    Tel: +44 (0)1294 317073

 Cavendish Capital Markets                                             Tel: +44 (0)20 7220 0500
 Limited

 (Nominated Adviser and Broker)

 Giles Balleny/Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Michael Johnson (Sales)

 

 

 About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the Group's four
trading businesses, each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 

 RUA Contract Manufacture:  End-to-end contract developer and manufacturer of medical devices and
                            implantable fabric specialist.

 RUA Biomaterials:          Licensor of Elast-Eon(TM) polymers to the medical device industry.

 RUA Vascular:              Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:      Development of polymeric leaflet systems for heart valves.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSSLSAMEISEFI